Biosimilars: Patient and Physician Acceptability Is the Fifth Hurdle to Market Competition

GaBI Journal - Belgium
doi 10.5639/gabij.2015.0401.002
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Pro Pharma Communications International

Related search

Biosimilars: Barriers and Opportunities to Market Access in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

FDA Biosimilar Action Plan: Could Improving Pharmacovigilance of Biologics Improve Patient and Physician Confidence in Biosimilars?

Expert Opinion on Drug Safety
MedicinePharmacology
2020English

Is Perfection Optimal? Employment and Product Market Competition

2002English

Php129 - Challenges and Opportunities in the Biologicals-Biosimilars Market: Sustainability and Market Differentiation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Assessing Physician and Patient Acceptance of Infliximab Biosimilars in Rheumatoid Arthritis, Ankylosing Spondyloarthritis and Psoriatic Arthritis Across Germany

Patient Preference and Adherence
PharmacologyHealth PolicyMedicineToxicologySocial SciencesPharmaceutics
2017English

Is Fair Market Competition Regulated Under Syariah Law?

Mediterranean Journal of Social Sciences
2014English

HLHS: First Operative Hurdle Is the Worst

Heart
2002English

Gender and Physician Differences in the Physician-Patient Discussion Prior to Open Access Colonoscopy

The Open Gastroenterology Journal
2011English

A European Perspective on the Market Accessibility of Biosimilars

Biosimilars
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy